Printer Friendly

STERLING WINTHROP AND ELF SANOFI ANNOUNCE JOINT DEVELOPMENT AND COMMERCIALIZATION OF TWO NEW AGENTS WITH BRISTOL-MYERS SQUIBB

 NEW YORK and PRINCETON, N.J., June 1 /PRNewswire/ -- Sterling Winthrop and Elf Sanofi, who forged their Sanofi Winthrop alliance in 1991, announced today preliminary agreements to jointly develop and market two promising cardiovascular compounds with Bristol-Myers Squibb Company (NYSE: BMY).
 The worldwide strategic cooperative effort involves the joint development and commercialization of an Elf Sanofi angiotensin II receptor antagonist for the treatment of hypertension and possibly other cardiovascular disorders, and clopidogrel, a novel antithrombotic agent for potential prevention of heart attack, stroke and peripheral arterial disease, which is currently being developed by the Elf Sanofi/Sterling Winthrop alliance.
 "We are pleased to combine these promising compounds with those of a firm well-established in cardiovascular medicine," said Jacques Rejeange, president, Sterling Winthrop Pharmaceuticals Group. "This unique opportunity to work with Bristol-Myers Squibb strongly complements our existing strategy and will further our efforts to become a worldwide leader in pharmaceuticals."
 "These agreements constitute a further acknowledgement of the quality of the pipeline, and offer expanded future prospects for these two compounds," said Kurt Briner, executive vice president, Pharmaceuticals Division of Elf Sanofi.
 "Bristol-Myers Squibb offers cardiovascular products for each major risk factor and each stage of the cardiovascular disease continuum, including hypertension, hypercholesterolemia, coronary artery disease, arrhythmias, and heart failure," said Kenneth E. Weg, president, Bristol-Myers Squibb Pharmaceutical Group. "This important agreement with Sterling Winthrop and Elf Sanofi will further strengthen our cardiovascular portfolio and provide some of the most advanced agents for prevalent cardiovascular disorders."
 The angiotensin II receptor antagonist is in Phase II clinical trials in Europe and entering Phase II trials in the United States. It is expected to offer an advantage over several types of drugs now available for treating hypertension. Clopidogrel, an antithrombotic agent, is in Phase III clinical trials worldwide. Potential indications include prevention of secondary myocardial infarction, stroke and peripheral arterial disease.
 Development activities for the two products will be shared by the companies. Sterling Winthrop Pharmaceuticals Research Division and Sanofi Research will continue to lead development efforts for clopidogrel and Bristol-Myers Squibb will lead the development effort for the angiotensin II receptor antagonist. Upon regulatory approval, marketing for each country will be handled on a country by country basis, and may include co-marketing, co-promotion and joint venture entity marketing.
 Definitive agreements are expected to be concluded within several months. The agreement also permits consideration of joint development of additional products at a later date.
 Bristol-Myers Squibb is a research-based, diversified healthcare company whose principle businesses are pharmaceuticals, consumer products, nutritionals and medical devices. It is among the world's leading makers of cardiovascular, anti-cancer, anti-infective, central nervous system and dermatological drug therapies, diagnostic agents and non-prescription medicines.
 Headquartered in New York City and Paris, Sterling Winthrop and Elf Sanofi develop, manufacture and market pharmaceutical products. These products are marketed worldwide through the Sanofi Winthrop alliance. The companies' research and development efforts are focused in: diagnostic imaging, oncology, chronic inflammatory diseases, cardiovascular disease, endocrine and metabolic diseases and disorders of the central nervous system.
 -0- 6/1/93
 /CONTACT: Carol J. Perlman, 212-907-2724, or Terry G. Kelley, 212-907-3009, both of Sterling Winthrop, or Peggy Ballman of Bristol- Myers Squibb, 609-252-5323/
 (BMY)


CO: Sterling Winthrop; Elf Sanofi; Bristol-Myers Squibb Company ST: New York, New Jersey IN: MTC SU:

LR-OS -- NY018 -- 3855 06/01/93 10:22 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 1, 1993
Words:551
Previous Article:VIEWLOGIC AUTOMATES DESIGN DATA MANAGEMENT IN ITS STANDARDS-BASED "OPENFRAME" FRAMEWORK
Next Article:ARGOSY GAMING ANNOUNCES OPENING OF ALTON BELLE CASINO II
Topics:


Related Articles
BRISTOL-MYERS SQUIBB ANNOUNCES AGREEMENT WITH SCHERING AG
BRISTOL-MYERS SQUIBB, STERLING WINTHROP INC. AND ELF SANOFI ANNOUNCE CARDIOVASCULAR DEVELOPMENT EFFORT
BRISTOL-MYERS SQUIBB, STERLING WINTHROP INC. AND ELF SANOFI ANNOUNCE CARDIOVASCULAR DEVELOPMENT EFFORT
STERLING WINTHROP AND ELF SANOFI ANNOUNCE FINAL AGREEMENT FOR JOINT DEVELOPMENT, COMMERCIALIZATION OF TWO AGENTS WITH BRISTOL-MYERS SQUIBB
BRISTOL-MYERS SQUIBB, STERLING WINTHROP AND ELF SANOFI FINALIZE CARDIOVASCULAR DEVELOPMENT AGREEMENT
ENZON GRANTS BRISTOL-MYERS SQUIBB LICENSE FOR SCA(R) PROTEIN TECHNOLOGY
Bristol-Myers Squibb Acquires Beraprost For Claudication From Hoechst Marion Roussel
Bristol-Myers Squibb and Cubist Pharmaceuticals Announce First Milestone Payment in Potential $56 Million Collaboration For Anti-Infective Drugs
Bristol-Myers Squibb Acquires Novel Antifungal From Eisai
Sanofi and Bristol-Myers Squibb Receive Clearance to Market PLAVIX(R)

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters